Susceptibility to antifungal drugs of Candida albicans isolated from upper respiratory tract of patients with chronic hepatitis C
More details
Hide details
Department of Pharmaceutical Microbiology, Medical University, Lublin, Poland
Department of Infectious Diseases, Medical University, Lublin, Poland
Corresponding author
Anna Biernasiuk   

Department of Pharmaceutical Microbiology, Medical University, Lublin, Poland
J Pre Clin Clin Res. 2013;7(2):111-113
Patients with chronic HCV infection due to itheir mmunocompromised status are predisposed to opportunistic infections caused by microorganisms of normal microflora, e.g. fungal infections caused especially by yeast species belonging to Candida spp., mainly Candida albicans.

The aim of this study was to analyze the drug susceptibility of Candida albicans colonizing the pper respiratory tract isolated from 100 patients with chronic hepatitis C from group I (without antiviral herapy) and from group II (treated with peginterferon and ribavirin).

Material and Methods:
The 30 isolates of C. albicans from group I and 31 isolates from group II were identified by standard methods – biochemical microtest API 20 C AUX (bioMérieux). The drug sensitivity to antifungal drugs (amphotericin B, flucytosine, fluconazole, itraconazole, ketoconazole and miconazole) was estimated by the Fungitest method (Sanofi Diagnostics Pasteur).

Among the isolates of C. albicans, 100% sensitivity to flucytosine and amphotericin B was found, irrespective of the patient group. However, a decreased sensitivity to azole derivates – miconazole, ketoconazole, itraconazole or fluconazole – was noted, amounting to 3.33 – 56.67% in the isolates from group I, while in group II amounting 9.68 – 48.39%, depending on the antifungal drugs. The isolates resistant to ketoconazole (6.67%) or itraconazole (10%) were found in group I, while resistant to miconazole (9.68%), ketoconazole (19.35%), itraconazole (22.58%) or fluconazole (3.22%) in group II.

Determination of drug sensitivity of the isolated yeast species should be the basis of rational and successful therapy.

Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51(4): 1176–84.
Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ, ACTG 5071 Study Team. Antigenspecific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005; 19(8): 767–73.
Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ, ACTG 5071 Study Team. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006; 20(3): 345–51.
Moreno A, Cervera C, Fortún J, Blanes M, Montejo E, Abradelo M, Len O, Rafecas A, Martín-Davila P, Torre-Cisneros J, Salcedo M, Cordero E, Lozano R, Pérez I, Rimola A, Miró JM. OLT-HIV FIPSE cohort investigators. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl. 2012; 18(1): 70–81.
Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Nonalbicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res. 2012; 136(6): 997–1003.
Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47(3): 1068–1071.
Biernasiuk A, Mahorowska-Kiciak I, Grzegorczyk A, Malm A. In vitro susceptibility of pharyngeal isolates of Candida albicans to some antifungal drugs. Ann UMCS. 2006; 61(2): 802–805.
Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997; 25(1): 103–7.
Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis. 2001, 1: 47–52.
Sulka A, Simon K, Piszko P, Kalecińska E, Dominiak M. Oral mucosa alterations in chronic hepatitis and cirrhosis due to HBV or HCV infection. Bull Group Int Rech Sci Stomatol Odontol. 2006; 47(1): 6–10.
Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician. 2010; 81(11): 1351–7.
Biernasiuk A, Korona-Głowniak I, Mahorowska-Kiciak I, Rybojad P, Malm A. Pharyngeal Candida spp. strains in patients with non-small cell lung cancer. Mikol Lek. 2006; 13(2): 89–93.
Grossmann SM, Teixeira R, de Aguiar MC, de Moura MD, do Carmo MA. Oral mucosal conditions in chronic hepatitis C Brazilian patients: a cross-sectional study. J Public Health Dent. 2009; 69(3): 168–75.
Williams DW, Lewis MAO. Isolation and identification of Candida,from the oral cavity. Oral Dis. 2000; 6(1): 3–11.
Nagao Y, Hashimoto K, Sata M. Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases. BMC Gastroenterol. 2012; 2(12): 155.
Krajewska-Kułak E, Niczyporuk W, Łukaszuk C, Krawczuk-Rybak M, Wojtukiewicz M, Kułak W, Sobaniec H. Usefulness of Fungitest in the estimation of susceptibility of the yeast-like fungi to antifungal in cancer patients. Mikol Lek. 1999; 6(4): 213–219.
Zomorodian K, Rahimi MJ, Kayvan P, Motamedi MMR, Hasanein R. Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis. 2011; 3(4): 357–360.
Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, Belyhun Y, Biadglegne F, Hurissa Z, Moges F, Isogai E. Frequent detection of azole resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis. 2013; 13(1): 82.
Jin-Sol L, Jong HS, Kyungwon L, Mi-Na K, Bo-Moon S, Young U, Wee-Gyo L, Hye SL, Chulhun LCh, Soo HK, Myung GS, Soon PS, Dong WR. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J. 2007; 48(5): 779–786.
Journals System - logo
Scroll to top